Design, Synthesis and Structure−Activity Relationships of Novel Taxane-Based Multidrug Resistance Reversal Agents
Iwao Ojima(Stony Brook University), Ralph J. Bernacki, Maria R. Baer(University of Maryland, Baltimore), Matthew B. Sturm, Paula Pera, Tracy A. Brooks(Roswell Park Comprehensive Cancer Center), C. Oderda(Roswell Park Comprehensive Cancer Center), Christopher P. Borella(Roswell Park Comprehensive Cancer Center), Michael L. Miller(Columbia University Irving Medical Center), Xinyuan Wu(Roswell Park Comprehensive Cancer Center), Qing Huang(Roswell Park Comprehensive Cancer Center), Pierre‐Yves Bounaud(Roswell Park Comprehensive Cancer Center), Subrata Chakravarty(Roswell Park Comprehensive Cancer Center), Jin Chen(Sichuan University)
Cited by 35
Related Papers
Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML
|New England Journal of Medicine|2019|1.3k
KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study
|The Lancet|2021|795
<i>IDH1</i> and <i>IDH2</i> Gene Mutations Identify Novel Molecular Subsets Within De Novo Cytogenetically Normal Acute Myeloid Leukemia: A Cancer and Leukemia Group B Study
|Journal of Clinical Oncology|2010|764